Medical Affairs
Innoviva Specialty Therapeutics has created this website as a tool for healthcare professionals in the United States. The information presented on this platform is solely for informational purposes and is not meant to advertise or endorse the use of any particular product.
Publications & Presentations
Information provided in these publications, posters and presentations is intended for scientific review by medical professionals. This information is not considered medical advice and is not intended to promote the sale of any drug product.
For more information on GIAPREZA, including important safety information, please visit www.GIAPREZA.com.
For more information on XERAVA, including important safety information, please visit www.XERAVA.com.
For more information on XACDURO, including important safety information, please visit www.XACDURO.com.
Filter by Product
No results
GIAPREZA®
Effects of angiotensin II in the management of perioperative hypotension in kidney transplant recipientsResource Type
Publication
Author Name
Andrews
Date Published
July 2023
XACDURO®
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)Resource Type
Publication
Author Name
Kaye
Date Published
May 2023
GIAPREZA®
Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trialResource Type
Publication
Author Name
Wieruszewski
Date Published
May 2023
XACDURO®
Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) InfectionsResource Type
Publication
Author Name
Watkins
Date Published
May 2023
XERAVA®
In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancerResource Type
Publication
Author Name
Rolston
Date Published
March 2023
Zoliflodacin
GyrB in silico mining in 27 151 global gonococcal genomes from 1928–2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibilityResource Type
Publication
Author Name
Golparian
Date Published
October 2022
XERAVA®
Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumanniiResource Type
Publication
Author Name
Alosaimy
Date Published
October 2022
GIAPREZA®
A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgeryResource Type
Publication
Author Name
Coulson
Date Published
September 2022
XACDURO®
In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021Resource Type
Publication
Author Name
Karlowsky
Date Published
August 2022
GIAPREZA®
Angiotensin II enhances bacterial clearance via myeloid signaling in a murine sepsis modelResource Type
Publication
Author Name
Leisman
Date Published
August 2022
XERAVA®
IN VITRO SURVEILLANCE OF ERAVACYCLINE AGAINST GRAM-POSITIVE PATHOGENS, INCLUDING RESISTANT ISOLATES, COLLECTED WORLDWIDE DURING 2020Resource Type
Publication
Author Name
Hawser
Date Published
April 2022
XERAVA®
Assessing the Real-world Clinical Outcomes of Patients Treated with Eravacycline for Complicated Intra-abdominal InfectionsResource Type
Publication
Author Name
Alosaimy
Date Published
April 2022
Zoliflodacin
Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection ModelResource Type
Publication
Author Name
Jacobsson
Date Published
April 2022
Zoliflodacin
Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy AdultsResource Type
Publication
Author Name
Newman
Date Published
November 2021
XERAVA®
A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitalsResource Type
Publication
Author Name
Hobbs
Date Published
November 2021
XERAVA®
Evaluation of Predictors of Clinical Success in Patients Treated with Eravacycline for Various InfectionsResource Type
Publication
Author Name
Alosaimy
Date Published
October 2021
XERAVA®
In Vitro Activity of Eravacycline Against Clinically Significant Bacteria Isolated from Patients with CancerResource Type
Publication
Author Name
Gerges
Date Published
October 2021
GIAPREZA®
Serum renin and major adverse kidney events in critically ill patients: a multicenter prospective studyResource Type
Publication
Author Name
Flannery
Date Published
August 2021
XACDURO®
Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With SulbactamResource Type
Publication
Author Name
Shapiro
Date Published
July 2021
XERAVA®
Eravacycline pharmacokinetics in a critically ill patient receiving venovenous extracorporeal membrane oxygenation and continuous venovenous haemodialysisResource Type
Publication
Author Name
Igneri
Date Published
July 2021
GIAPREZA®
Angiotensin II for Near Drowning: A Case SeriesResource Type
Publication
Author Name
Smith
Date Published
May 2021
Zoliflodacin
Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection ModelResource Type
Publication
Author Name
Jacobsson
Date Published
May 2021
XACDURO®
A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjectsResource Type
Publication
Author Name
O'Donnell
Date Published
May 2021
GIAPREZA®
Commentary: Angiotensin II: Expanding the rescue options for vasoplegiaResource Type
Publication
Author Name
Augoustides
Date Published
April 2021
GIAPREZA®
Commentary: Is angiotensin II a game changer for vasoplegia after cardiac surgery, or is the jury still out?Resource Type
Publication
Author Name
Chatterjee
Date Published
March 2021
GIAPREZA®
Evaluating the evidence for angiotensin II for the treatment of vasoplegia in critically ill cardiothoracic surgery patientsResource Type
Publication
Author Name
Chow
Date Published
March 2021
Zoliflodacin
Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Neisseria gonorrhoeae Clinical Isolates in Nanjing, China, 2014 to 2018Resource Type
Publication
Author Name
Le
Date Published
February 2021
XACDURO®
In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia SpeciesResource Type
Publication
Author Name
Papp-Wallace
Date Published
February 2021
GIAPREZA®
Intraoperative Use of Angiotensin II for Severe Vasodilatory Shock During Liver Transplantation: A Case ReportResource Type
Publication
Author Name
Running
Date Published
February 2021
Zoliflodacin
High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018Resource Type
Publication
Author Name
Unemo
Date Published
February 2021
GIAPREZA®
A Multicenter Observational Cohort Study of Angiotensin II in ShockResource Type
Publication
Author Name
Smith
Date Published
November 2020
XERAVA®
Efficacy and Tolerability of Eravacycline in Bacteremic Patients with Complicated Intra-Abdominal Infection: A Pooled Analysis from the IGNITE1 and IGNITE4 StudiesResource Type
Publication
Author Name
Felice
Date Published
November 2020
XERAVA®
Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical TrialsResource Type
Publication
Author Name
Asempa
Date Published
November 2020
XERAVA®
Tomefa E Asempa, Sergey Izmailyan, Kenneth Lawrence, David P NicolauResource Type
Publication
Author Name
Alosaimy
Date Published
October 2020
XERAVA®
A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel FluorocyclineResource Type
Publication
Author Name
Hise
Date Published
October 2020
GIAPREZA®
Angiotensin II Administration in Patients With COVID-19 ShockResource Type
Publication
Author Name
Ofosu-Barko
Date Published
October 2020
XERAVA®
In vitro activity of eravacycline against common ribotypes of Clostridioides difficileResource Type
Publication
Author Name
Bassères
Date Published
October 2020
GIAPREZA®
Physiologic Response to Angiotensin II Treatment for Coronavirus Disease 2019–Induced Vasodilatory Shock: A Retrospective Matched Cohort StudyResource Type
Publication
Author Name
Leisman
Date Published
September 2020
XERAVA®
In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant EnterobacteriaceaeResource Type
Publication
Author Name
Clark
Date Published
September 2020
XERAVA®
Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and RegionResource Type
Publication
Author Name
Johnston
Date Published
September 2020
XERAVA®
Eravacycline, a novel tetracycline derivative, does not induce Clostridioides difficile infection in an in vitro human gut modelResource Type
Publication
Author Name
Buckley
Date Published
September 2020
GIAPREZA®
Vasopressor-Refractory Shock From Clozapine Overdose Treated With Synthetic Angiotensin II InfusionResource Type
Publication
Author Name
Wieruszewski
Date Published
September 2020
GIAPREZA®
Angiotensin II and Vasoplegia in Cardiac Surgery: Paradigm Changer or Costly Contender?Resource Type
Publication
Author Name
Chow
Date Published
September 2020
GIAPREZA®
Angiotensin II in Post Cardiopulmonary Bypass Vasoplegia – The Experience So FarResource Type
Publication
Author Name
Cutler
Date Published
September 2020
GIAPREZA®
Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing UseResource Type
Publication
Author Name
Wieruszewski
Date Published
August 2020
GIAPREZA®
Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injuryResource Type
Publication
Author Name
Leisman
Date Published
August 2020
GIAPREZA®
Angiotensin II for Critically Ill Patients With Shock After Heart TransplantResource Type
Publication
Author Name
Cutler
Date Published
August 2020
XERAVA®
Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018Resource Type
Publication
Author Name
Lutgring
Date Published
August 2020
GIAPREZA®
Successful use of angiotensin II for vasoplegia after thoracoabdominal aortic aneurysm repairResource Type
Publication
Author Name
Chatterjee
Date Published
August 2020
Zoliflodacin
Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea—challenges and opportunitiesResource Type
Publication
Author Name
Theuretzbacher
Date Published
August 2020
GIAPREZA®
Treatment of Renin-Angiotensin-Aldosterone System Dysfunction With Angiotensin II in High-Renin Septic ShockResource Type
Publication
Author Name
Chow
Date Published
August 2020
GIAPREZA®
Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) StudyResource Type
Publication
Author Name
Klijian
Date Published
August 2020
XERAVA®
In Vitro Activities of Eravacycline and Other Antimicrobial Agents against Human Mycoplasmas and UreaplasmasResource Type
Publication
Author Name
Waites
Date Published
July 2020
GIAPREZA®
Catecholamine-Sparing Effect of Angiotensin II in an Anephric Patient With Mixed Shock After Cardiac Revascularization Surgery: A Case ReportResource Type
Publication
Author Name
Cutler
Date Published
July 2020
GIAPREZA®
Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory ShockResource Type
Publication
Author Name
Bellomo
Date Published
July 2020
GIAPREZA®
Use of Angiotensin II in Severe Vasoplegia After Left Pneumonectomy Requiring Cardiopulmonary Bypass: A Renin Response AnalysisResource Type
Publication
Author Name
Trethowan
Date Published
July 2020
GIAPREZA®
Angiotensin II for the Treatment of COVID-19–Related Vasodilatory ShockResource Type
Publication
Author Name
Chow
Date Published
July 2020
GIAPREZA®
Angiotensin II for the treatment of septic shock in a neutropenic patient with T-cell acute lymphoblastic leukaemiaResource Type
Publication
Author Name
Bui
Date Published
June 2020
XACDURO®
Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy SubjectsResource Type
Publication
Author Name
Lickliter
Date Published
June 2020
XERAVA®
An Evaluation of Treatment Patterns and Associated Outcomes Among Adult Hospitalized Patients With Lower-Risk Community-Acquired Complicated Intra-abdominal Infections: How Often Are Expert Guidelines Followed?Resource Type
Publication
Author Name
Lodise
Date Published
June 2020
XACDURO®
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumanniiResource Type
Publication
Author Name
Seifert
Date Published
June 2020
XERAVA®
Real-world utilization of eravacycline in the outpatient settingResource Type
Publication
Author Name
Hwang
Date Published
May 2020
GIAPREZA®
A Patient With Tricyclic Antidepressant Overdose With Catecholamine-Resistant Hypotension Rescued With Angiotensin II: A Case ReportResource Type
Publication
Author Name
Ferdowsali
Date Published
May 2020
Zoliflodacin
Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant IsolatesResource Type
Publication
Author Name
Bradford
Date Published
April 2020
GIAPREZA®
Unexpected BP Sensitivity to Angiotensin II in a Patient With Coronavirus Disease 2019, ARDS, and Septic ShockResource Type
Publication
Author Name
Wang
Date Published
April 2020
XACDURO®
In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in ChinaResource Type
Publication
Author Name
Yang
Date Published
April 2020
GIAPREZA®
Effective Use of Angiotensin II in Coronavirus Disease 19–Associated Mixed Shock State: A Case ReportResource Type
Publication
Author Name
Bobeck
Date Published
April 2020
GIAPREZA®
COVID-19 and the RAAS—a potential role for angiotensin II?Resource Type
Publication
Author Name
Busse
Date Published
April 2020
XACDURO®
In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017Resource Type
Publication
Author Name
McLeod
Date Published
March 2020
XERAVA®
Early Experience With Eravacycline for Complicated InfectionsResource Type
Publication
Author Name
Alosaimy
Date Published
March 2020
GIAPREZA®
Angiotensin II for the treatment of distributive shock in the intensive care unit: A US costeffectiveness analysisResource Type
Publication
Author Name
Busse
Date Published
March 2020
XERAVA®
In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017Resource Type
Publication
Author Name
Morrissey
Date Published
February 2020
XACDURO®
Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute PyelonephritisResource Type
Publication
Author Name
Sagan
Date Published
February 2020
GIAPREZA®
Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shockResource Type
Publication
Author Name
Bellomo
Date Published
February 2020
GIAPREZA®
Another Role for Angiotensin II?: Vasopressin-Refractory Shock After Pheochromocytoma Resection: A Case ReportResource Type
Publication
Author Name
Hylton
Date Published
January 2020
XERAVA®
Real-World Use of Eravacycline: A Case SeriesResource Type
Publication
Author Name
Lunsted
Date Published
December 2019
XERAVA®
Carbapenem Treatment and Outcomes Among Patients With Culture-Positive Complicated Intra-abdominal Infections in US Hospitals: A Retrospective Cohort StudyResource Type
Publication
Author Name
Zilberberg
Date Published
November 2019
Zoliflodacin
High In Vitro Susceptibility to the First-in-Class Spiropyrimidinetrione Zoliflodacin among Consecutive Clinical Neisseria gonorrhoeae Isolates from Thailand and South AfricaResource Type
Publication
Author Name
Jacobsson
Date Published
November 2019
XERAVA®
Eravacycline for the treatment of complicated intra-abdominal infectionsResource Type
Publication
Author Name
Montravers
Date Published
October 2019
XERAVA®
An Evaluation of Empiric Treatment Patterns for Adult Patients with Community-Onset “Low-Risk” Complicated Intra-Abdominal Infections Across US HospitalsResource Type
Publication
Author Name
Lodise
Date Published
October 2019
XERAVA®
In vitro AcJvity of Eravacycline, a New Tetracycline Analog, and comparators Against the Six Most commonly Isolated Ribotypes of Clostridioides difficileResource Type
Publication
Author Name
Bassères
Date Published
October 2019
XERAVA®
Activity of Eravacycline Against Contemporary Gram-negative Clinical Isolates from New York City HospitalsResource Type
Publication
Author Name
Khan
Date Published
October 2019
XERAVA®
Comparative evaluation of ETEST® ERV* bioMérieux with the CLSI broth microdilution method for Eravacycline MIC determinationResource Type
Publication
Author Name
SAUVONNET
Date Published
October 2019
XERAVA®
Predictors of empiric carbapenem therapy in complicated intra-abdominal infections in the US, 2013–2017: a retrospective cohort studyResource Type
Publication
Author Name
Zilberberg
Date Published
October 2019
XERAVA®
Novel Therapeutic Options for the Treatment of Multi-Drug Resistant Achromobacter Respiratory InfectionsResource Type
Publication
Author Name
Canonica
Date Published
October 2019
XERAVA®
In vitro activity and performance of available susceptibility testing methods for eravacycline against carbapenem-resistant EnterobacteriaceaeResource Type
Publication
Author Name
Jones
Date Published
October 2019
XERAVA®
Multicenter Evaluation of Eravacycline MIC Results for Enterobacteriaceae Using MicroScan Dried Gram Negative MIC PanelsResource Type
Publication
Author Name
Traczewski
Date Published
October 2019
XERAVA®
Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistanceResource Type
Publication
Author Name
Solomkin
Date Published
October 2019
XERAVA®
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site AdministrationResource Type
Publication
Author Name
Avery
Date Published
October 2019
GIAPREZA®
Angiotensin II in Decompensated Cirrhosis Complicated by Septic ShockResource Type
Publication
Author Name
Coleman
Date Published
September 2019
Zoliflodacin
Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor ZoliflodacinResource Type
Publication
Author Name
Miller
Date Published
August 2019
XACDURO®
Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control SubjectsResource Type
Publication
Author Name
O’Donnell
Date Published
August 2019
GIAPREZA®
Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two PatientsResource Type
Publication
Author Name
Bailey
Date Published
August 2019
GIAPREZA®
Successful Treatment of Antihypertensive Overdose Using Intravenous Angiotensin IIResource Type
Publication
Author Name
Carpenter
Date Published
July 2019
XERAVA®
Activity of Eravacycline and Comparators Against 15,872 Bacterial Pathogens Isolated from Patients Receiving Care in Canadian Hospitals: CANWARD 2014-18Resource Type
Publication
Author Name
BAXTER
Date Published
June 2019
XERAVA®
Activity of cefiderocol (CFDC), ceftazidime-avibactam (CZA), and eravacycline (ERV) against carbapenem-resistant (CR) E. coli isolates from the US: Clonal Background, Resistance Genes, and Co-ResistanceResource Type
Publication
Author Name
Johnson
Date Published
June 2019
XERAVA®
Comparative evaluation of Eravacycline MIC determination with the new ETEST® ERV* and CLSI broth microdilution methodResource Type
Publication
Author Name
PILLON
Date Published
June 2019
XERAVA®
Global In vitro Surveillance of Eravacycline Against Gram-negative and Gram-positive Clinical Isolates, Including Multidrug-Resistant Pathogens, Collected in 2017Resource Type
Publication
Author Name
Hwang
Date Published
June 2019
GIAPREZA®
Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trialResource Type
Publication
Author Name
Ham
Date Published
June 2019
XERAVA®
In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessusResource Type
Publication
Author Name
Kaushik
Date Published
May 2019
XERAVA®
Multi-Site Evaluation of Eravacycline MIC Test Strip (MTS) Compared To Broth Microdilution MICsResource Type
Publication
Author Name
OLESKY
Date Published
May 2019
GIAPREZA®
Synthetic Human Angiotensin II for Postcardiopulmonary Bypass Vasoplegic ShockResource Type
Publication
Author Name
Wieruszewski
Date Published
May 2019
XERAVA®
Multicenter Evaluation of Eravacycline MIC Results for E. coli Using MicroScan Dried Gram Negative MIC PanelsResource Type
Publication
Author Name
Garner
Date Published
April 2019
GIAPREZA®
Use of Angiotensin II for Vasoplegic Shock in a Combined Heart and Liver Transplant Recipient with Systolic Anterior Motion PhysiologyResource Type
Publication
Author Name
Wieruszewski
Date Published
March 2019
XACDURO®
Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic AgentResource Type
Publication
Author Name
Barnes
Date Published
March 2019
XERAVA®
Eravacycline: A Review in Complicated Intra-Abdominal InfectionsResource Type
Publication
Author Name
Scott
Date Published
February 2019
Zoliflodacin
Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy VolunteersResource Type
Publication
Author Name
O’Donnell
Date Published
December 2018
XERAVA®
IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal InfectionsResource Type
Publication
Author Name
Solomkin
Date Published
December 2018
GIAPREZA®
Angiotensin II Use in Refractory Multisystem Shock: A Case ReportResource Type
Publication
Author Name
Ahmed
Date Published
November 2018
Zoliflodacin
Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital GonorrheaResource Type
Publication
Author Name
Taylor
Date Published
November 2018
GIAPREZA®
Angiotensin in ECMO patients with refractory shockResource Type
Publication
Author Name
Ostermann
Date Published
November 2018
GIAPREZA®
Angiotensin converting enzyme defects in shock: implications for future therapyResource Type
Publication
Author Name
Chawla
Date Published
October 2018
XACDURO®
Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult SubjectsResource Type
Publication
Author Name
Rodvold
Date Published
October 2018
GIAPREZA®
When All Else Fails: Novel Use of Angiotensin II for Vasodilatory Shock: A Case ReportResource Type
Publication
Author Name
Chow
Date Published
October 2018
XERAVA®
Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of EravacyclineResource Type
Publication
Author Name
Newman
Date Published
August 2018
GIAPREZA®
FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive ShockResource Type
Publication
Author Name
Senatore
Date Published
August 2018
XERAVA®
In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides speciesResource Type
Publication
Author Name
Goldstein
Date Published
July 2018
XERAVA®
In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacyclineResource Type
Publication
Author Name
Zhang
Date Published
June 2018
XERAVA®
Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in RabbitsResource Type
Publication
Author Name
Petraitis
Date Published
June 2018
XERAVA®
Microbiological Efficacy of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including MDR Isolates: A Pooled Analysis from IGNITE1 and IGNITE4, Two Phase 3 Trials of Complicated Intra-Abdominal InfectionResource Type
Publication
Author Name
Ditch
Date Published
June 2018
GIAPREZA®
Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin IIResource Type
Publication
Author Name
Tumlin
Date Published
June 2018
XERAVA®
Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic IsolatesResource Type
Publication
Author Name
Snydman
Date Published
May 2018
XERAVA®
Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysisResource Type
Publication
Author Name
Thabit
Date Published
May 2018
Zoliflodacin
In vitro activity of zoliflodacin (ETX0914) against macrolide-resistant, fluoroquinolone-resistant and antimicrobial-susceptible Mycoplasma genitalium strainsResource Type
Publication
Author Name
Damião Gouveia
Date Published
February 2018
XACDURO®
Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumanniiResource Type
Publication
Author Name
McLeod
Date Published
January 2018
XERAVA®
In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumanniiResource Type
Publication
Author Name
Seifert
Date Published
January 2018
GIAPREZA®
The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literatureResource Type
Publication
Author Name
Busse
Date Published
December 2017
XACDURO®
Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant PorinResource Type
Publication
Author Name
Iyer
Date Published
December 2017
XACDURO®
Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by SulbactamResource Type
Publication
Author Name
Shapiro
Date Published
November 2017
XERAVA®
In Vitro Activity of Eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides speciesResource Type
Publication
Author Name
Citron,
Date Published
October 2017
XERAVA®
Impact of Meal Timing on Eravacycline Exposure During the Oral Portion of an IV to Oral Transition Dosing RegimenResource Type
Publication
Author Name
Horn
Date Published
October 2017
XACDURO®
Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514Resource Type
Publication
Author Name
Shapiro
Date Published
August 2017
GIAPREZA®
Angiotensin II for the Treatment of Vasodilatory ShockResource Type
Publication
Author Name
Khanna
Date Published
August 2017
GIAPREZA®
Clinical Experience With IV Angiotensin II Administration: A Systematic Review of SafetyResource Type
Publication
Author Name
Busse
Date Published
August 2017
XERAVA®
In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection ModelResource Type
Publication
Author Name
Zhao
Date Published
July 2017
XACDURO®
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumanniiResource Type
Publication
Author Name
Durand-Réville
Date Published
June 2017
XERAVA®
Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical TrialResource Type
Publication
Author Name
Solomkin
Date Published
March 2017
XERAVA®
A Divergent Route to EravacyclineResource Type
Publication
Author Name
Zhang
Date Published
December 2016
Zoliflodacin
In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrioneResource Type
Publication
Author Name
Papp
Date Published
July 2016
XERAVA®
In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumanniiResource Type
Publication
Author Name
Livermore
Date Published
June 2016
Zoliflodacin
Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodentsResource Type
Publication
Author Name
Guo
Date Published
April 2016
XERAVA®
Review of Eravacycline, a Novel Fluorocycline Antibacterial AgentResource Type
Publication
Author Name
Zhanel
Date Published
April 2016
Zoliflodacin
Effect of Susceptibility Testing Conditions on the In Vitro Antibacterial Activity of ETX0914Resource Type
Publication
Author Name
Giacobbe
Date Published
March 2016
Zoliflodacin
Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914)Resource Type
Publication
Author Name
Hong Su
Date Published
December 2015
Zoliflodacin
Genetic Resistance Determinants, In Vitro Time-Kill Curve Analysis and Pharmacodynamic Functions for the Novel Topoisomerase II Inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeaeResource Type
Publication
Author Name
Foerster
Date Published
December 2015
Zoliflodacin
In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative PathogensResource Type
Publication
Author Name
Biedenbach
Date Published
September 2015
Zoliflodacin
Update on Treatment Options for Gonococcal InfectionsResource Type
Publication
Author Name
Lancaster
Date Published
September 2015
Zoliflodacin
High In Vitro Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (AZD0914) among 873 Contemporary Clinical Neisseria gonorrhoeae Isolates from 21 European Countries from 2012 to 2014Resource Type
Publication
Author Name
Unemo
Date Published
August 2015
Zoliflodacin
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesResource Type
Publication
Author Name
Basarab
Date Published
July 2015
Zoliflodacin
Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)Resource Type
Publication
Author Name
Basarab
Date Published
July 2015
Zoliflodacin
In Vitro Antibacterial Activity of AZD0914 against Human Mycoplasmas and UreaplasmasResource Type
Publication
Author Name
Waites
Date Published
May 2015
XERAVA®
Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York CityResource Type
Publication
Author Name
Abdallah
Date Published
March 2015
Zoliflodacin
Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria gonorrhoeaeResource Type
Publication
Author Name
Alm
Date Published
February 2015
XACDURO®
Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumanniiResource Type
Publication
Author Name
Penwell
Date Published
February 2015
Zoliflodacin
In Vitro Antibacterial Activity of AZD0914, a New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-Positive, Fastidious Gram-Negative, and Atypical BacteriaResource Type
Publication
Author Name
Huband
Date Published
December 2014
Zoliflodacin
Synthesis of a Tetrahydronaphthyridine Spiropyrimidinetrione DNA Gyrase Inhibiting Antibacterial Agent – Differential Substitution at all Five Carbon Atoms of Pyridine.Resource Type
Publication
Author Name
Basarab
Date Published
December 2014
Zoliflodacin
In Vitro Activity of AZD0914, a Novel DNA Gyrase Inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniaeResource Type
Publication
Author Name
Kohlhoff
Date Published
November 2014
GIAPREZA®
Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot studyResource Type
Publication
Author Name
Chawla
Date Published
October 2014
Zoliflodacin
Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo CharacterizationResource Type
Publication
Author Name
Basarab
Date Published
October 2014
Zoliflodacin
High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of GonorrheaResource Type
Publication
Author Name
Jacobsson
Date Published
August 2014
XERAVA®
Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal InfectionsResource Type
Publication
Author Name
Solomkin
Date Published
April 2014
XERAVA®
Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and WomenResource Type
Publication
Author Name
Connors
Date Published
January 2014
XERAVA®
Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community PathogensResource Type
Publication
Author Name
Sutcliffe
Date Published
November 2013
XERAVA®
Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical DevelopmentResource Type
Publication
Author Name
Ronn
Date Published
April 2013
XERAVA®
Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline AntibioticResource Type
Publication
Author Name
Grossman
Date Published
February 2012
XERAVA®
Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad Spectrum Antibacterial AgentResource Type
Publication
Author Name
Xiao
Date Published
December 2011
Zoliflodacin
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914Resource Type
Publication
Author Name
Kern
Date Published
September 2023
Zoliflodacin
Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection—Clinical Trial Group Programmatic MeetingResource Type
Publication
Author Name
Cristillo
Date Published
September 2023